Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2020 Gastrointestinal Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCC
Dr. O'Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic Cancer
Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial
Oncology Conference Articles
QoL Superior With Atezolizumab/Bevacizumab Versus Sorafenib in Frontline HCC
Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.
Triplet and Doublet Regimens Outperform Standard of Care on Survival, QoL in BRAF+ CRC
Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with
V600E-mutant metastatic colorectal cancer.
Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC
Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.
Second-Line Ramucirumab Improves OS in AFP-Elevated HCC, Regardless of Disease Stage
Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.
Bekaii-Saab Sheds Light on Furthering Biomarker-Driven Treatment in GI Cancers
Tanios S. Bekaii-Saab, MD, examines the effectiveness of umbrella trials and their importance in aiding precision medicine in gastrointestinal oncology.
High Responses Observed With Avelumab Added to Regimen for Metastatic Colorectal Cancer Does Not Translate to PFS
A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with
-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.
Kopetz Highlights Improved QoL, Efficacy With Encorafenib Regimens in
Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with
V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.
Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC
The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.
Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer
The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline
Frontline Lenvatinib with Subsequent Therapy Improves Survival in Unresectable HCC
Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.
Addition of Cabozantinib to Ipi/Nivo Shows Promising Antitumor Activity in Advanced HCC
The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.
Nivolumab/Ramucirumab Plus Chemo Highly Active in Second-Line Gastric Cancer
The triplet of nivolumab, ramucirumab and paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.
Larotrectinib Efficacy Confirmed in TRK+ GI Cancer
The efficacy of larotrectinib has been confirmed in patients with heavily pretreated TRK fusion–positive gastrointestinal cancers.
Pembrolizumab Shows Enhanced Efficacy in High PD-L1 Gastric Cancer
Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.
Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers
A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.
ASCO GU 2020: Dr. Taplin Highlights Ongoing Research in Prostate Cancer
Community Oncologist Discusses CAR T-Cell Therapy and Other Hematology Advances
Dr. Heyman on the Use of Maintenance Rituximab in Follicular Lymphoma
Real-World Evidence Should Be Part of Clinical Trials in Oncology
Dr. Marshall on Challenges in CRC Treatment
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.